Should I Buy TDOC? TDOC 2026 Analysis

Should You Buy Teladoc Health Inc (TDOC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

5.010

1 Day change

5.92%

52 Week Range

15.210

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

TDOC is not a good buy right now for an impatient investor. Despite being extremely oversold (RSI~13), the prevailing trend is decisively bearish (bearish MA stack and expanding negative MACD), and the near-term news flow is materially negative with Medicare telehealth coverage rolling off after Jan 31. With no Intellectia buy signals to override the setup, the path of least resistance remains down/volatile into the Feb-25 earnings event.

Technical Analysis

Trend/structure: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling a sustained downtrend rather than a simple dip. Momentum: MACD histogram is -0.104 and negatively expanding, implying downside momentum is still strengthening. Mean-reversion/oversold: RSI_6 at 13.27 is deeply oversold, which can produce short, sharp bounces—but oversold in a strong downtrend is not a reliable “buy now” signal, especially with negative catalysts. Levels: Pivot 5.976 overhead is the first reclaim level. Nearby supports: S1 5.548 (already being tested) and S2 5.284 (next downside magnet if weakness continues). Resistances: R1 6.404 then R2 6.668. Pattern-based odds: Similar-pattern analysis suggests a 60% chance of ~-3.09% next day, but slightly positive drift over 1 week (+2.66%) and 1 month (+6.18%)—i.e., a choppy oversold bounce is possible, but near-term risk remains elevated.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put-call ratios are very low (OI PCR 0.35; Volume PCR 0.2), indicating call-skewed positioning and a relatively bullish/contrarian sentiment in options. Volatility: 30D IV ~69.37 vs historical vol ~76.5 (still very high absolute vol). IV percentile ~50 and IV rank ~38.45 suggest IV is not at an extreme versus its own history, but the stock remains a high-vol name. Liquidity/activity: Today’s volume (19.7k) is ~69% of the 30-day average, so sentiment is skewed bullish, but not backed by unusually heavy options volume today. Takeaway: Options skew leans bullish/short-cover-bounce-friendly, but the high-vol environment and weak tape mean options are not confirming a durable bottom.

Technical Summary

Sell

Buy

Positive Catalysts

increases probability of a reflex bounce.
on 2026-02-25 could act as a catalyst if guidance or margins surprise positively.

Neutral/Negative Catalysts

- Major near-term policy/headline risk: Medicare ending broad telehealth coverage (except rural patients in facilities) after Jan 31; multiple news items cite potential demand impact for Teladoc.
- Price action is still trending down (bearish MA stack; expanding negative MACD), implying sellers remain in control.
- Business fundamentals remain challenged: slow/negative revenue growth and unprofitability noted in news; macro/consumer pressure cited for BetterHelp trends.
- High volatility environment increases downside air pockets during negative headlines.

Financial Performance

Latest reported quarter: 2025/Q3.

Revenue: $626.439M, down -2.20% YoY (top-line contraction).
Net income: -$49.507M, improved 48.78% YoY (loss narrowing).
EPS: -0.28, improved 47.37% YoY (still negative).
Gross margin: 56.01%, down -11.85% YoY (margin compression). Bottom line: Profitability is improving from a loss-reduction standpoint, but revenue is shrinking and margins deteriorated—weak quality of improvement and not the profile that typically supports aggressive dip-buying.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Price targets have been repeatedly cut into early 2026, while ratings are mostly Neutral/Equal Weight with a minority Buy.

BofA: Neutral; PT cut to $7 (from $7.50 on 2026-01-27; earlier cuts from $9 to $8 to $7.50).
Citi: Neutral; PT cut to $9 (from $10 on 2026-01-09).
Goldman Sachs: Maintains Buy; PT cut to $8-$9 range (from $10-$9).
Barclays: Initiated Equal Weight; PT $8.50.
BMO: Market Perform; PT $8. Wall Street pros vs cons: Pros: Teladoc remains a category leader; some analysts see potential normalization where organic growth drives valuation; potential BetterHelp insurance channel/intl stabilization could help. Cons: Consistent price-target compression reflects lower multiples and skepticism; growth has slowed post-pandemic; policy-driven telehealth demand risk is rising; continued losses keep the risk profile high. Influential/political trading: No recent congress trading data available; hedge funds and insiders show Neutral activity with no significant recent trends.

TDOC Should I Buy